NFKB1 and prostate carcinoma: To computationally estimate the true and false positive prediction rates of our approach, we compared our predictions with (1) a prostate cancer-specific co-expression analysis, (2) known mechanisms from the NFκB signaling pathway in BioCarta (BioCarta.com, BioCarta LLC), and (3) known mechanisms from literature.